Form 8-K - Current report:
SEC Accession No. 0001999371-25-002866
Filing Date
2025-03-20
Accepted
2025-03-20 09:21:41
Documents
14
Period of Report
2025-03-19
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ird-8k_031925.htm   iXBRL 8-K 30521
2 AMENDED AND RESTATED BYLAWS OF OPUS GENETICS, INC. ex3-1.htm EX-3.1 169302
  Complete submission text file 0001999371-25-002866.txt   418714

Data Files

Seq Description Document Type Size
3 XBRL LABEL FILE ird-20250319_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE ird-20250319_pre.xml EX-101.PRE 22362
5 XBRL SCHEMA FILE ird-20250319.xsd EX-101.SCH 3076
16 EXTRACTED XBRL INSTANCE DOCUMENT ird-8k_031925_htm.xml XML 3794
Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709 248-681-9815
Opus Genetics, Inc. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 25754681
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)